Mobilization For Autologous Transplantation In Non Hodgkin's Lymphoma Or Multiple Myeloma Therapeutics
1. Mozobil patent expiration
Treatment: Use in combination with granulocyte-colony stimulating factor (g-csf) to mobilize hematopoietic stem cells to peripheral blood for collection & subsequent autologous transplantation in patients with n...
MOZOBIL's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| USRE42152 | GENZYME | Aromatic-linked polyamine macrocyclic compounds with anti-HIV activity |
Dec, 2018
(7 years ago) | |
| US6987102 | GENZYME | Methods to mobilize progenitor/stem cells |
Jul, 2023
(2 years ago) | |
| US7897590 | GENZYME | Methods to mobilize progenitor/stem cells |
Jul, 2023
(2 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Dec 15, 2013 |
| Orphan Drug Exclusivity(ODE) | Dec 15, 2015 |
Drugs and Companies using PLERIXAFOR ingredient
NCE-1 date: 15 December, 2012
Market Authorisation Date: 15 December, 2008
Dosage: SOLUTION
How can I launch a generic of MOZOBIL before it's drug patent expiration?
More Information on Dosage
MOZOBIL family patents
